Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 14/12/2019
SIETES contiene 92854 citas

 
 
 1 a 20 de 46 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Avery AJ, Bell BG. Rationalising medications through deprescribing. BMJ 2019;364:7 de febrero. [Ref.ID 103031]
2. Cita con resumen
Reeve E, Ong M, Wu A, Jansen J, Petrovic M, Gnjidic D. A systematic review of interventions to deprescribe benzodiazepines and other hypnotics among older people. Eur J Clin Pharmacol 2017;73:927-35. [Ref.ID 101927]
3. Cita con resumen
Prada-Ramallal G, Takkouche B, Figueiras A. Diverging conclusions from the same meta-analysis in drug safety: source of data (primary versus secondary) takes a toll. Drug Saf 2017;40:351-8. [Ref.ID 101501]
4. Cita con resumen
Herr M, Robine J-M, Pinot J, Arvieu J-J, Ankri J. Polypharmacy and frailty: prevalence, relationship, and impact on mortality in a French sample of 2350 old people. Pharmacoepidemiol Drug Saf 2015;24:637-46. [Ref.ID 99854]
5. Cita con resumen
Vicens C, Bejarano F, Sempere E, Mateu C, Fiol F, Socias I, Aragonès E, Palop V, Beltran JL, Piñol JL, Lera G, Folch S, Mengual M, Basora J, Esteva M, Llobera J, Roca M, Gili M, Leiva A. Comparative efficacy of two interventions to discontinue long-term benzodiazepine use: cluster randomised controlled trial in primary care. Br J Psychiatry 2014;204:471-9. [Ref.ID 97332]
6. Cita con resumen
Pérez-Llobet S, Rey MV, Fabre N, Ory F, Spampinato U, Montastruc J-L, Rascol O. Do Parkinson's disease patients disclose their adverse events spontaneously?. Eur J Clin Pharmacol 2012;68:857-65. [Ref.ID 92830]
7. Cita con resumen
Gama H, Correia S, Lunet N. Questionnaire design and the recall of pharmacological treatments: a systematic review. Pharmacoepidemiol Drug Saf 2009;18:175-87. [Ref.ID 85438]
8. Cita con resumen
Weissman JS, Schneider EC, Weingart SN, Epstein AM, David-Kasdan J, Feibelmann S, Annas CL, Ridley N, Kirle L, Gatsonis C. Comparing patient-reported hospital adverse events with medical record review: do patients know something that hospitals do not?. Ann Intern Med 2008;149:100-8. [Ref.ID 83600]
9.
Faber A, Keizer RJ, van den Berg PB, de Jon-van den Berg LTW, Tobi H. Use of double-blind placebo-controlled N-of-1 trials among stimulant-treated youths in The Netherlands: a descriptive study. Eur J Clin Pharmacol 2007;63:57-63. [Ref.ID 79048]
10.
Lovell K, Cox D, Haddock G, Jones C, Raines D, Garvey R, Roberts C, Hadley S. Telephone administered cognitive behaviour therapy for treatment of obsessive compulsive disorder: randomised controlled non-inferiority trial. BMJ 2006;333:883-6. [Ref.ID 78439]
11.
Hamann J, Kolbe G, Cohen R, Leucht S, Kissling W. How do psychiatrists choose among different antipsychotics?. Eur J Clin Pharmacol 2005;61:851-4. [Ref.ID 75702]
12.
Glintborg B, Andersen SE, Spang-Hanssen E, Dalhoff K. Disregarded use of herbal medical products and dietary supplements among surgical and medical patients as estimated by home inspection and interview. Pharmacoepidemiol Drug Saf 2005;14:639-45. [Ref.ID 75029]
14. Cita con resumen
Gil Garcia E, Romo Avilés N, Poo Ruiz M, Meneses Falcón C, Markez Alonso I, Vega Fuente A. Género y psicofármacos: la opinión de los prescriptores a través de una investigación cualitativa. Aten Primaria 2005;35:402-7. [Ref.ID 74003]
15.
Levinson W, Kao A, Kuby AM, Thisted RA. The effect of physician disclosure of financial incentives on trust. Arch Intern Med 2005;165:625-30. [Ref.ID 73453]
16.
Obome CA, Luzac ML. Over-the-counter medicine use prior to and during hospitalization. Ann Pharmacother 2005;39:268-73. [Ref.ID 72897]
17.Tiene citas relacionadas
Finckh A, Aronson MD. Cardiovascular risks of cyclooxygenase-2 inhibitors: where we stand now. Ann Intern Med 2005;142:212-4. [Ref.ID 72727]
18.Tiene citas relacionadas
Jain A, Atreja A, Harris CM, Lehmann M, Burns J, Young J. Responding to the rofecoxib withdrawal crisis: a new model for notifying patients at risk and their health care providers. Ann Intern Med 2005;142:182-6. [Ref.ID 72725]
19.Tiene citas relacionadas Cita con resumen
Kimmel PL, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Strom BL. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005;142:157-64. [Ref.ID 72722]
20.
Weingart SN, Gandhi TK, Seger AC, Seger DL, Borus J, Burdick E, Leape LL, Bates DW. Patient-reported medication symptoms in primary care. Arch Intern Med 2005;165:234-40. [Ref.ID 72660]
Seleccionar todas
 
 1 a 20 de 46 siguiente >>